RT Journal Article
SR Electronic
T1 Estimates of presumed population immunity to SARS-CoV-2 by state in the United States, August 2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.17.21263759
DO 10.1101/2021.09.17.21263759
A1 Stoner, Marie C.D.
A1 Angulo, Frederick J.
A1 Rhea, Sarah
A1 Brown, Linda Morris
A1 Atwell, Jessica E.
A1 Nguyen, Jennifer L.
A1 McLaughlin, John
A1 Swerdlow, David L.
A1 MacDonald, Pia D.M.
YR 2021
UL http://medrxiv.org/content/early/2021/09/21/2021.09.17.21263759.abstract
AB Background Information is needed to monitor progress toward a level of population immunity to SARS-CoV-2 sufficient to disrupt viral transmission. We estimated the percentage of the United States (US) population with presumed immunity to SARS-CoV-2 due to vaccination, natural infection, or both as of August 26, 2021.Methods Publicly available data as of August 26, 2021, from the Centers for Disease Control and Prevention (CDC) were used to calculate presumed population immunity by state. Seroprevalence data were used to estimate the percentage of the population previously infected with SARS-CoV-2, with adjustments for underreporting. Vaccination coverage data for both fully and partially vaccinated persons were used to calculate presumed immunity from vaccination. Finally, we estimated the percentage of the total population in each state with presumed immunity to SARS-CoV-2, with a sensitivity analysis to account for waning immunity, and compared these estimates to a range of population immunity thresholds.Results Presumed population immunity varied among states (43.1% to 70.6%), with 19 states with 60% or less of their population having been infected or vaccinated. Four states have presumed immunity greater than thresholds estimated to be sufficient to disrupt transmission of less infectious variants (67%), and none were greater than the threshold estimated for more infectious variants (78% or higher).Conclusions The US remains a distance below the threshold sufficient to disrupt viral transmission, with some states remarkably low. As more infectious variants emerge, it is critical that vaccination efforts intensify across all states and ages for which the vaccines are approved.Summary As of August 26, 2021, no state has reached a population level of immunity thought to be sufficient to disrupt transmission. (78% or higher), with some states having remarkably low presumed immunity.Competing Interest StatementFrederick Angulo, Jessica Atwell, John McLaughlin, Jennifer Nguyen, and David Swerdlow are employees of and hold stock and stock options in Pfizer Inc.Funding StatementThis work was supported by funding from Pfizer to RTI for data collection, analysis, and manuscript development by Marie Stoner, Sarah Rhea, Linda Brown and Pia MacDonald who are employees of RTI.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ExemptAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available by contacting the corresponding author